Abstract:Atherosclerotic thrombosis is the leading cause of most life-threatening cardiovascular diseases (CVDs), particularly as a result of rupture or erosion of vulnerable plaques. Rupture or erosion-prone plaques are quite different in cellular composition and immunopathology, requiring different treatment strategies. The current imaging technology cannot distinguish the types of vulnerable plaques, and thus empirical treatment is still applied to all without a tailored and precise treatment. Herein, we propose a novel strategy called "Multifunctional Pathology-mapping Theranostic Nanoplatform (MPmTN)" for the tailored treatment of plaques based on the pathological classification. MPmTNs are made up of poly(lactic-co-glycolic acid) (PLGA) nanoparticles (NPs), containing contrast imaging materials Fe3O4 and perfluoropentane (PFP), and coated with specific plaque-targeted peptides PP1 and cyclic RGD. The PFP encapsulated inside the MPmTN can undergo a phase change from nanodroplets to gas microbubbles under therapeutic ultrasound (TUS) exposure. The acoustic and biological effects induced by TUS and disruption of microbubbles may further promote therapeutic effects. Hypothetically, MPmTN NPs can target the rupture-prone plaque via the binding of PP1 to class A scavenger receptors (SR-A) on macrophages, induce the apoptosis due to TUS exposure and thus reduce the chronic soakage of inflammatory cells. The MPmTN NPs can also target the erosion-prone plaque through the binding of cRGD to glycoprotein (GP) IIb/IIIa on activated platelets and promote platelet disaggregation under TUS exposure. Therefore, MPmTNs may work as a multifunctional pathology-mapping therapeutic agent. Our in vitro results show that the MPmTN with PP1 and cRGD peptides had a high binding affinity both for activated macrophages and blood clots. Under TUS exposure, the MPmTN could effectively induce macrophage apoptosis, destroy thrombus and exhibit good imaging properties for ultrasound (US) and MRI. In apoE-/- mice, MPmTNs can selectively accumulate at the plaque site and reduce the T2-weighted signal. The apoptosis of macrophages and disaggregation of activated platelets on the plaques were also confirmed in vivo. In summary, this study provides a potential strategy for a tailored treatment of vulnerable plaques based on their pathological nature and a multimodal imaging tool for the risk stratification and assessment of therapeutic efficacy.

Biomimetic Synthesis of Neutrophil-Microbubble for Robust in Vivo Targeting of Atherosclerotic Vulnerable Plaques

Bionic Microbubble Neutrophil Composite for Inflammation-Responsive Atherosclerotic Vulnerable Plaque Pluripotent Intervention.

ROS-responsive Biomimetic Nanovesicles to Plaque Microenvironment in Targeted Therapy of Atherosclerosis

Platelet Membrane Biomimetic Nanoparticles Combined With UTMD to Improve the Stability of Atherosclerotic Plaques

Ultrasound-assisted Biomimetic Nanobubbles for Targeted Treatment of Atherosclerosis

Application of Therapeutical Nanoparticles with Neutrophil Membrane Camouflaging for Inflammatory Plaques Targeting against Atherosclerosis

Biomimetic Nanotherapies: Red Blood Cell Based Core–Shell Structured Nanocomplexes for Atherosclerosis Management

Nanoparticle Functionalization with Platelet Membrane Enables Multifactored Biological Targeting and Detection of Atherosclerosis

Biomimetic Nanoparticles for the Diagnosis and Therapy of Atherosclerosis

Identifying Macrophage Enrichment in Atherosclerotic Plaques by Targeting Dual-Modal US Imaging/mri Based on Biodegradable Fe-doped Hollow Silica Nanospheres Conjugated with Anti-Cd68 Antibody

Biomimetic nanoparticles: U937 cell membranes based core–shell nanosystems for targeted atherosclerosis therapy

Recent progress in biomimetic nanomedicines based on versatile targeting strategy for atherosclerosis therapy

Platelet-derived Nanomotor Coated Balloon for Atherosclerosis Combination Therapy.

Platelet‐Mimicking Therapeutic System for Noninvasive Mitigation of the Progression of Atherosclerotic Plaques

Ultrasound Molecular Imaging of Atherosclerosis for Early Diagnosis and Therapeutic Evaluation through Leucocyte-like Multiple Targeted Microbubbles.

Multifunctional pathology-mapping theranostic nanoplatforms for US/MR imaging and ultrasound therapy of atherosclerosis

Biomimetic nanomedicines for precise atherosclerosis theranostics

Circulating Monocyte Differentiation-Activated Nanoprodrugs for Reprogramming Macrophage Immunity in Atherosclerotic Plaques

A Dual-Targeting Therapeutic Nanobubble for Imaging-Guided Atherosclerosis Treatment

A preliminary study on the biomimetic drug delivery system targeting atherosclerotic lesions

Pro-efferocytic macrophage membrane biomimetic nanoparticles for the synergistic treatment of atherosclerosis via competition effect